GLP-1 Receptor Agonists and Kidney Protection
Type 2 diabetes mellitus (T2DM) is the leading cause of chronic kidney disease (CKD). Diabetic nephropathy (DN) is determined by specific pathological structural and functional alterations of the kidneys in patients with diabetes, and its clinical manifestations are albuminuria and decline of glomer...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-05-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1010-660X/55/6/233 |
| _version_ | 1827835249920311296 |
|---|---|
| author | Eulalia Valentina Greco Giuseppina Russo Annalisa Giandalia Francesca Viazzi Roberto Pontremoli Salvatore De Cosmo |
| author_facet | Eulalia Valentina Greco Giuseppina Russo Annalisa Giandalia Francesca Viazzi Roberto Pontremoli Salvatore De Cosmo |
| author_sort | Eulalia Valentina Greco |
| collection | DOAJ |
| description | Type 2 diabetes mellitus (T2DM) is the leading cause of chronic kidney disease (CKD). Diabetic nephropathy (DN) is determined by specific pathological structural and functional alterations of the kidneys in patients with diabetes, and its clinical manifestations are albuminuria and decline of glomerular filtration rate (GFR). Apart from renin−angiotensin−aldosterone system (RAAS) inhibitors, no other drugs are currently available as therapy for diabetic kidney disease (DKD). Glucagon-like peptide-1 receptor (GLP-1R) agonists are a new class of anti-hyperglycemic drugs which have been demonstrated to prevent the onset of macroalbuminuria and reduce the decline of GFR in diabetic patients. These drugs may exert their beneficial actions on the kidneys through blood glucose- and blood pressure (BP)-lowering effects, reduction of insulin levels and weight loss. Clinical benefits of GLP-1R agonists were acknowledged due to data from large randomized phase III clinical trials conducted to assess their cardiovascular(CV) safety. These drugs improved renal biomarkers in placebo-controlled clinical studies, with effects supposed to be independent of the actions on glycemic control. In this review, we will focus on the actions of GLP-1R agonists on glucose metabolism and kidney physiology, and evaluate direct and indirect mechanisms through which these drugs may confer renal protection. |
| first_indexed | 2024-03-12T06:04:55Z |
| format | Article |
| id | doaj.art-949ff62bca5940fcac8250da2f561ba6 |
| institution | Directory Open Access Journal |
| issn | 1010-660X |
| language | English |
| last_indexed | 2024-03-12T06:04:55Z |
| publishDate | 2019-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-949ff62bca5940fcac8250da2f561ba62023-09-03T03:45:07ZengMDPI AGMedicina1010-660X2019-05-0155623310.3390/medicina55060233medicina55060233GLP-1 Receptor Agonists and Kidney ProtectionEulalia Valentina Greco0Giuseppina Russo1Annalisa Giandalia2Francesca Viazzi3Roberto Pontremoli4Salvatore De Cosmo5Unit of Internal Medicine, Department of Medical Sciences, IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo (FG), ItalyDepartment of Clinical and Experimental Medicine, University of Messina, 98121 Messina, ItalyDepartment of Clinical and Experimental Medicine, University of Messina, 98121 Messina, ItalyDepartment of Internal Medicine, University of Genoa and Policlinico San Martino-IST, 16131 Genoa, ItalyDepartment of Internal Medicine, University of Genoa and Policlinico San Martino-IST, 16131 Genoa, ItalyUnit of Internal Medicine, Department of Medical Sciences, IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo (FG), ItalyType 2 diabetes mellitus (T2DM) is the leading cause of chronic kidney disease (CKD). Diabetic nephropathy (DN) is determined by specific pathological structural and functional alterations of the kidneys in patients with diabetes, and its clinical manifestations are albuminuria and decline of glomerular filtration rate (GFR). Apart from renin−angiotensin−aldosterone system (RAAS) inhibitors, no other drugs are currently available as therapy for diabetic kidney disease (DKD). Glucagon-like peptide-1 receptor (GLP-1R) agonists are a new class of anti-hyperglycemic drugs which have been demonstrated to prevent the onset of macroalbuminuria and reduce the decline of GFR in diabetic patients. These drugs may exert their beneficial actions on the kidneys through blood glucose- and blood pressure (BP)-lowering effects, reduction of insulin levels and weight loss. Clinical benefits of GLP-1R agonists were acknowledged due to data from large randomized phase III clinical trials conducted to assess their cardiovascular(CV) safety. These drugs improved renal biomarkers in placebo-controlled clinical studies, with effects supposed to be independent of the actions on glycemic control. In this review, we will focus on the actions of GLP-1R agonists on glucose metabolism and kidney physiology, and evaluate direct and indirect mechanisms through which these drugs may confer renal protection.https://www.mdpi.com/1010-660X/55/6/233type 2 diabetes mellitusdiabetic kidney diseasealbuminuriaglucagon-like peptide-1 receptor agonistkidney protection |
| spellingShingle | Eulalia Valentina Greco Giuseppina Russo Annalisa Giandalia Francesca Viazzi Roberto Pontremoli Salvatore De Cosmo GLP-1 Receptor Agonists and Kidney Protection Medicina type 2 diabetes mellitus diabetic kidney disease albuminuria glucagon-like peptide-1 receptor agonist kidney protection |
| title | GLP-1 Receptor Agonists and Kidney Protection |
| title_full | GLP-1 Receptor Agonists and Kidney Protection |
| title_fullStr | GLP-1 Receptor Agonists and Kidney Protection |
| title_full_unstemmed | GLP-1 Receptor Agonists and Kidney Protection |
| title_short | GLP-1 Receptor Agonists and Kidney Protection |
| title_sort | glp 1 receptor agonists and kidney protection |
| topic | type 2 diabetes mellitus diabetic kidney disease albuminuria glucagon-like peptide-1 receptor agonist kidney protection |
| url | https://www.mdpi.com/1010-660X/55/6/233 |
| work_keys_str_mv | AT eulaliavalentinagreco glp1receptoragonistsandkidneyprotection AT giuseppinarusso glp1receptoragonistsandkidneyprotection AT annalisagiandalia glp1receptoragonistsandkidneyprotection AT francescaviazzi glp1receptoragonistsandkidneyprotection AT robertopontremoli glp1receptoragonistsandkidneyprotection AT salvatoredecosmo glp1receptoragonistsandkidneyprotection |